Navigation Links
ViroPharma to Present at Three November Healthcare Conferences
Date:11/6/2008

EXTON, Pa., Nov. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Rodman & Renshaw Annual Global Investment Conference at 12:25 P.M. ET on Wednesday, November 12, 2008. The conference is being held at the New York Palace Hotel.

ViroPharma also announced that Colin Broom, vice president, chief scientific officer of ViroPharma will present at the Lazard Capital Markets 5th Annual Healthcare Conference at 9:30 A.M. ET on Wednesday, November 19, 2008. The conference is being held at the St. Regis Hotel in New York.

William Roberts, vice president, corporate communications of ViroPharma will present at the Needham & Company Focus on Infectious Disease Conference at 9:30 A.M. ET on Thursday, November 20, 2008. The conference is being held at Needham & Company's corporate headquarters in New York.

ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
2. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
3. ViroPharma to Present at Three October Healthcare Conferences
4. ViroPharma to Present at Three September Healthcare Conferences
5. ViroPharma To Acquire Lev Pharmaceuticals
6. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
7. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
10. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
11. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... India , Jan. 19, 2017  Market Research Future has ... Global Market for Liquid Biopsy is growing rapidly and expected to ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a ... growth figures and boom in the coming future. There has been ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of ... Material, Application - Forecast to 2025" report to their ... The report provides a detailed analysis on current and ... forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017 ... company that supports the entire spectrum of clinical ... been another record-breaking year for the organization in ... interest in MedNet,s eClinical products and services. The ... tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):